Keyword Analysis & Research: vertex clinical trial vx 814


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
vertex clinical trial vx 8141.40.973236428
vertex0.870.9680156
clinical1.460.51919768
trial0.3911720995
vx1.570.8768542
8140.730.165483

Keyword Research: People who searched vertex clinical trial vx 814 also searched

Keyword CPC PCC Volume Score
vertex vx-880 clinical trial0.660.950196
vertex pharmaceuticals clinical trials1.350.3888291
vx 548 clinical trial0.940.1712361
vertex apol1 clinical trial1.731652664
vx 880 clinical trial1.960.2577156
vertex standard vx 4260.320.2658129
vertex standard vx 22000.65171020
vtx-0811 clinical trial0.240.2374482
vertex vx-5481.30.8698032
vertex pharmaceuticals diabetes trial1.080.531021
news about vertex pharmaceuticals1.020.5845436
vertex pharmaceuticals summary and analysis0.410.9118318
vertex pharmaceuticals recent news1.470.9825991
vertex pharmaceuticals fda approval0.640.2919592
invest in vertex pharmaceuticals0.921802893
vertex pharmaceuticals new drug1.630.3695432
vertex pharmaceuticals global markets0.94134415
vertex pharmaceuticals current market1.220.213029
vertex pharmaceuticals stock analysis0.771181163
vertex pharmaceuticals traded as0.830.7222341
what is vertex pharmaceuticals1.740.3294759
vertex pharmaceuticals business development1.20.3557484
vertex pharmaceuticals stock news1.630.9542098
vertex pharmaceuticals inc stock1.480.9689855
vertex clinical pharmacology linkedin0.670.6457451
new york times vertex pharmaceuticals0.191606416
vertex pharmaceuticals medicine list1.060.1665463
stock price vertex pharmaceuticals1.17177454
vertex pharmaceuticals pricing graph1.710.7585277
vertex pharmaceuticals incorporated stock0.620.229816
vx-880 clinical trial0.70.4645172
vertex pharmaceuticals vx-8801.23145483
vx-880 clinical trial sign up0.860.252281
vertex vx-8800.320.9252830

Search Results related to vertex clinical trial vx 814 on Search Engine

  • Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency

    vrtx.com

    https://investors.vrtx.com/news-releases/news-release-details/vertex-advances-program-targeting-alpha-1-antitrypsin-deficiency

    WEBPDF Version. Oct 11, 2022. Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency. - Initiates first …

    DA: 67 PA: 44 MOZ Rank: 66

  • Vertex Provides Update on its Clinical Programs Targeting Alpha …

    vrtx.com

    https://investors.vrtx.com/news-releases/news-release-details/vertex-provides-update-its-clinical-programs-targeting-alpha-1

    WEBOct 14, 2020 · The randomized, double-blind, placebo-controlled Phase 2 study of approximately 50 patients was …

    DA: 47 PA: 33 MOZ Rank: 16

  • R&D Pipeline | Alpha-1 Antitrypsin Deficien…

    vrtx.com

    https://www.vrtx.com/our-science/pipeline/alpha-1-antitrypsin-deficiency/

    DA: 46 PA: 90 MOZ Rank: 27

  • Vertex Abandons VX-814 Program for Treating Rare Liver Disease

    biospace.com

    https://www.biospace.com/article/vertex-kills-program-for-vx-814-to-treat-rare-liver-disease/

    WEBOct 15, 2020 · Photo courtesy of Vertex Pharmaceuticals. Vertex Pharmaceuticals announced that based on early data of its Phase II trial of VX-814 in Alpha-1 antitrypsin deficiency (AATD), it is halting the trial and ending development of the drug. AATD is a genetic disease resulting in a missing liver protein.

    DA: 56 PA: 9 MOZ Rank: 17

  • Vertex Provides Update on its Clinical Programs Targeting Alpha …

    businesswire.com

    https://www.businesswire.com/news/home/20201014005787/en/Vertex-Provides-Update-on-its-Clinical-Programs-Targeting-Alpha-1-Antitrypsin-Deficiency

    WEBOct 14, 2020 · Based on the safety and pharmacokinetic (PK) profile of VX-814 observed to date in a Phase 2 trial in …

    DA: 85 PA: 5 MOZ Rank: 71


  • Vertex Provides Update on its Clinical Programs Targeting ... - N…

    nasdaq.com

    https://www.nasdaq.com/press-release/vertex-provides-update-on-its-clinical-programs-targeting-alpha-1-antitrypsin

    WEBOct 14, 2020 4:30PM EDT. - Phase 2 study of VX-814 in patients with alpha-1 antitrypsin deficiency discontinued …

    DA: 34 PA: 97 MOZ Rank: 28

  • Evaluation of the Efficacy and Safety of VX-814 in Subjects With the

    clinicaltrials.gov

    https://classic.clinicaltrials.gov/ct2/show/NCT04167345

    WEBNov 18, 2019 · Results First Posted : February 2, 2022. Last Update Posted : February 2, 2022. View this study on …

    DA: 68 PA: 94 MOZ Rank: 74

  • Vertex hits a biomarker bump on road to new drug

    biopharmadive.com

    https://www.biopharmadive.com/news/vertex-hits-a-biomarker-bump-on-road-to-new-drug/563097/

    WEBSep 17, 2019 · Vertex aims to treat the disorder with VX-814, an experimental therapy that should yield Phase 2 proof …

    DA: 71 PA: 62 MOZ Rank: 89

  • R&D Pipeline | Alpha-1 Antitrypsin Deficiency - Vertex

    vrtx.com

    https://www.vrtx.com/our-science/pipeline/alpha-1-antitrypsin-deficiency/

    WEBAlpha-1 antitrypsin deficiency (AATD) is an inherited disease that can cause damage to both the lungs and the liver. …

    DA: 19 PA: 37 MOZ Rank: 18